La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sernova Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Sernova sono diminuiti a un tasso annuo medio di -52%, mentre il settore Biotechs ha visto gli utili crescere a un tasso annuo di 11.8%.

Informazioni chiave

-49.6%

Tasso di crescita degli utili

-41.5%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	-14.6%
Tasso di crescita dei ricavi	n/a
Rendimento del capitale proprio	n/a
Margine netto	n/a
Ultimo aggiornamento sui guadagni	31 Jul 2024

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

Ripartizione dei ricavi e delle spese

Come Sernova guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

XTRA:PSH Ricavi, spese e utili (CAD Millions )
Data	Guadagni	Spese G+A	Spese di R&S
31 Jul 24	-39	9	30
30 Apr 24	-41	9	33
31 Jan 24	-41	10	32
31 Oct 23	-39	8	32
31 Jul 23	-36	8	29
30 Apr 23	-31	8	24
31 Jan 23	-27	7	21
31 Oct 22	-24	8	17
31 Jul 22	-18	7	12
30 Apr 22	-14	5	9
31 Jan 22	-11	4	7
31 Oct 21	-7	2	5
31 Jul 21	-6	2	3
30 Apr 21	-5	2	3
31 Jan 21	-5	2	3
31 Oct 20	-5	3	3
31 Jul 20	-6	3	3
30 Apr 20	-6	3	3
31 Jan 20	-5	3	2
31 Oct 19	-4	2	2
31 Jul 19	-3	1	2
30 Apr 19	-3	1	2
31 Jan 19	-4	1	2
31 Oct 18	-4	1	2
31 Jul 18	-4	1	2
30 Apr 18	-3	1	2
31 Jan 18	-3	1	2
31 Oct 17	-3	1	2
31 Jul 17	-2	1	1
30 Apr 17	-2	1	1
31 Jan 17	-2	1	1
31 Oct 16	-2	1	1
31 Jul 16	-3	1	2
30 Apr 16	-3	1	2
31 Jan 16	-3	1	2
31 Oct 15	-3	1	2
31 Jul 15	-3	1	2
30 Apr 15	-3	1	2
31 Jan 15	-3	1	2
31 Oct 14	-3	1	2
31 Jul 14	-3	1	2
30 Apr 14	-2	1	2
31 Jan 14	-2	1	2

Guadagni di qualità: PSH al momento non è redditizia.

Margine di profitto in crescita: PSH al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: PSH non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 52% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di PSH nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: PSH non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( -0.08% ).

Rendimento del capitale proprio

ROE elevato: Le passività di PSH superano le sue attività, quindi è difficile calcolare il suo rendimento del capitale proprio.

Sernova Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Recent updates

Sernova Corp. Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Corp. announced that it has received CAD 5.2 million in funding

Independent Director recently sold €149k worth of stock

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Less than half of directors are independent

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

New major risk - Share price stability

New minor risk - Market cap size

Sernova Corp., Annual General Meeting, Apr 30, 2024

New minor risk - Financial position

New minor risk - Share price stability

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Chairman recently bought €162k worth of stock

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

New major risk - Financial position

Sernova Corp. Announces Executive Changes

Less than half of directors are independent

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

No longer forecast to breakeven

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Forecast to breakeven in 2024

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Chief Financial Officer recently bought €51k worth of stock

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate